Xintela AB (publ) (STO:XINT)
Sweden · Delayed Price · Currency is SEK 0.1680
+0.0030 (1.82%)
Sep 2, 2026, 3:48 PM CET
Xintela AB Market Cap
Xintela AB has a market cap or net worth of 144.69 million as of September 2, 2026. Its market cap has decreased by -46.83% in one year.
Market Cap
144.69M
Enterprise Value
143.97M
Revenue
3.03M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.17
ChartMarket Cap Chart
Since March 22, 2016, Xintela AB's market cap has increased from 103.68M to 144.69M, an increase of 39.56%. That is a compound annual growth rate of 3.24%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 2, 2026 | 144.69M | -27.17% |
| Dec 30, 2025 | 198.68M | 5.85% |
| Dec 30, 2024 | 187.69M | 26.87% |
| Dec 29, 2023 | 147.94M | -1.74% |
| Dec 30, 2022 | 150.56M | -26.24% |
| Dec 30, 2021 | 204.12M | 2.23% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Xbrane Biopharma AB | 195.75M |
| Elicera Therapeutics AB | 190.20M |
| Alzinova AB | 170.22M |
| Abera Bioscience AB | 166.86M |
| Nanologica AB | 161.10M |
| Diamyd Medical AB | 160.25M |
| Initiator Pharma | 157.44M |
| NextCell Pharma AB | 139.03M |